Molecules, Vol. 24, Pages 2685: Long-Acting Injectable Statins —Is It Time for a Paradigm Shift?

Molecules, Vol. 24, Pages 2685: Long-Acting Injectable Statins—Is It Time for a Paradigm Shift? Molecules doi: 10.3390/molecules24152685 Authors: Lee M. Tatham Neill J. Liptrott Steve P. Rannard Andrew Owen In recent years, advances in pharmaceutical processing technologies have resulted in development of medicines that provide therapeutic pharmacokinetic exposure for a period ranging from weeks to months following a single parenteral administration. Benefits for adherence, dose and patient satisfaction have been witnessed across a range of indications from contraception to schizophrenia, with a range of long-acting medicines also in development for infectious diseases such as HIV. Existing drugs that have successfully been formulated as long-acting injectable formulations have long pharmacokinetic half-lives, low target plasma exposures, and low aqueous solubility. Of the statins that are clinically used currently, atorvastatin, rosuvastatin, and pitavastatin may have compatibility with this approach. The case for development of long-acting injectable statins is set out within this manuscript for this important class of life-saving drugs. An overview of some of the potential development and implementation challenges is also presented.
Source: Molecules - Category: Chemistry Authors: Tags: Opinion Source Type: research

Related Links:

CONCLUSIONS: Some, but not all agents with anti-inflammatory properties showed efficacy. Effective agents were aspirin, estrogens, minocycline, and NAC. We observed greater beneficial results on symptom severity in FEP or early-phase schizophrenia. PMID: 31439071 [PubMed - as supplied by publisher]
Source: Psychological Medicine - Category: Psychiatry Authors: Tags: Psychol Med Source Type: research
Novel therapy development in psychiatry is at an impasse, with a significant lull since the 1980s and 1990s when most of the monoamine-targeted therapies that form the foundation of modern practice were first launched. The monoaminergic targets of such therapies have failed to deliver novel treatments. Instead, some of the most promising novel therapies have arisen from the twin biomarker findings of increased inflammation and oxidative stress across the major psychiatric disorders, including depression, schizophrenia, and bipolar disorder. Research on inflammation and oxidative stress has led to the identification of prom...
Source: JAMA Psychiatry - Category: Psychiatry Source Type: research
I spend half my week in a community clinic working with a lot of folks with schizophrenia or bipolar 1 so have fair number on SGAs either PO or LAI. I’m constantly getting lipid panels back that are off the chain, refer to primary care and seems less than 20% of patients ever actually go. Currently I would never consider prescribing statins because I’m not up on guidelines, but has gotten me starting to wonder. I can check any labs I want and presumably it’s not rocket science to follow... Would you ever consider prescribing statins?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Psychiatry Source Type: forums
Jiangshan J. Shen1,2,3, Yong-Fei Wang1† and Wanling Yang1* 1Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong 2Collaborative Innovation Center for Birth Defect Research and Transformation of Shandong Province, Jining Medical University, Jining, China 3Lupus Research Institute, Affiliated Hospital of Jining Medical University, Jining, China Despite sex being an important epidemiological and physiological factor, not much is known about how sex works to interact with genotypes to result in different phenotypes. Both messen...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Drug-repurposing research suggests a role for statins, calcium channel blockers, and metformin in treating schizophrenia and other serious mental illness.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Psychiatry News Source Type: news
Common medications used to fight cholesterol, high blood pressure, and diabetes may be useful in lowering risk of self-harm and psychiatric hospitalization for people with a serious mental illness (SMI) such as bipolar disorder, schizophrenia, or nonaffective psychosis, according to astudy published yesterday inJAMA Psychiatry.In the study, Joseph F. Hayes, Ph.D., of University College London and an international team of colleagues analyzed data from the health records of 142,691 Swedish patients aged 15 and older who had an SMI and were treated with psychiatric medication from October 2005 through December 2016. The data ...
Source: Psychiatr News - Category: Psychiatry Tags: bipolar disorder JAMA Psychiatry Joseph Hayes L-type calcium channel blockers medications Metformin nonaffective psychosis psychiatric hospitalization schizophrenia self-harm statins Source Type: research
This study shows that some genetic changes linked to cancer are present in surprisingly large numbers of normal cells. We still have a long way to go to fully understand the implications of these new findings, but as cancer researchers, we can't underestimate the importance of studying healthy tissue." Early Onset of Menopause Correlates with Shorter Life Expectancy Aging is a phenomenon affecting all organs and systems throughout the body, driven by rising levels of molecular damage. The v...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
The increased risk of mortality in patients with schizophrenia can be reduced with cardioprotective medication, such as antiplatelets, β-blockers, and statins, after a heart attack, suggests astudy published inJAMA Psychiatry.Previous studies have found that patients with schizophrenia die 10 to 15 years younger and have worse outcomes from coronary artery disease than those in the general population.“Our study suggests that patients with schizophrenia who are treated with cardioprotective treatment after MI [myocardial infarction] have a lower mortality risk compared with patients who are not treated, similar t...
Source: Psychiatr News - Category: Psychiatry Tags: antiplatelets Benjamin Druss Denmark heart attack JAMA Psychiatry Pirathiv Kugathasan schizophrenia statins β-blockers Source Type: research
Conclusions. J Clin Psychiatry. 2018 Sep 25;79(5): Authors: Andrade C Abstract A very large number of psychopharmacologic agents have been trialed as antipsychotic augmentation strategies for the improvement of positive, negative, mood, cognitive, and other symptoms of schizophrenia; statins are one among these. Two very recent meta-analyses examined data on statin augmentation from 5 to 6 randomized controlled trials (RCTs) in the field. One meta-analysis found that statins were superior to placebo for the improvement of total scale and general psychopathology subscale scores on the Positive and Negat...
Source: Journal of Clinical Psychiatry - Category: Psychiatry Tags: J Clin Psychiatry Source Type: research
More News: Atorvastatin Calcium | Chemistry | Cholesterol | Crestor | Infectious Diseases | Lipitor | Rosuvastatin | Schizophrenia | Statin Therapy | Zivast